tadalafil has been researched along with macitentan in 13 studies
| Studies (tadalafil) | Trials (tadalafil) | Recent Studies (post-2010) (tadalafil) | Studies (macitentan) | Trials (macitentan) | Recent Studies (post-2010) (macitentan) |
|---|---|---|---|---|---|
| 1,742 | 392 | 1,089 | 233 | 34 | 214 |
| Protein | Taxonomy | tadalafil (IC50) | macitentan (IC50) |
|---|---|---|---|
| Endothelin receptor type B | Rattus norvegicus (Norway rat) | 0.391 | |
| Endothelin receptor type B | Homo sapiens (human) | 0.5897 | |
| Endothelin-1 receptor | Homo sapiens (human) | 0.0015 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (30.77) | 24.3611 |
| 2020's | 9 (69.23) | 2.80 |
| Authors | Studies |
|---|---|
| Watanabe, H | 1 |
| Ahmed, AA; Elnakish, MT; Floyd, K; Janssen, PM; Mohler, PJ; Saad, NS | 1 |
| Benjamin, N; Burhenne, J; Egenlauf, B; Enderle, Y; Fischer, C; Grünig, E; Haefeli, WE; Harutyunova, S; Huppertz, A; Klose, H; Ohnesorge, J | 1 |
| Dweik, RA; Heresi, GA; Highland, KB; Love, TE; Tonelli, AR | 1 |
| Miyasaka, A; Morino, Y; Suzuki, A; Takikawa, Y; Ueda, H; Yoshida, Y | 1 |
| Amiya, E; Asano, Y; Hatano, M; Komuro, I; Kubota, K; Maki, H; Minatsuki, S; Morita, H; Sato, S; Yoshizaki, A | 1 |
| Bergot, E; Bertoletti, L; Bouvaist, H; Canuet, M; Clerson, P; Cottin, V; Gressin, V; Perchenet, L; Picard, F; Prévot, G; Simonneau, G; Sitbon, O | 1 |
| Antonova, M; Bruderer, S; Carlson, J; Csonka, D; Globig, S; Grill, S; Schultz, A; Sidharta, PN | 1 |
| Burki, TK | 1 |
| Kam, CW; Ruiz, FE | 1 |
| Chin, KM; Doelberg, M; Feldman, J; Galiè, N; Gibbs, JSR; Grünig, E; Hoeper, MM; Martin, N; Mathai, SC; McLaughlin, VV; Perchenet, L; Poch, D; Saggar, R; Simonneau, G; Sitbon, O | 1 |
| Armas, D; Csonka, D; Dishy, V; Fishman, V; Natarajan, J; Perez Ruixo, JJ; Stieltjes, H | 1 |
| Bai, C; Giannakoulas, G; Hohenforst-Schmidt, W; Huang, H; Karapantzou, C; Kioumis, I; Kosmidis, C; Matthaios, D; Petanidis, S; Petridis, D; Pitsiou, G; Sardeli, C; Tsakiridis, K; Zarogoulidis, P | 1 |
2 review(s) available for tadalafil and macitentan
| Article | Year |
|---|---|
[Pharmacological treatment of pulmonary hypertension at a turning point].
Topics: Administration, Oral; Adult; Antihypertensive Agents; Bosentan; Carbolines; Endothelin Receptor Antagonists; Epoprostenol; Female; Humans; Hypertension, Pulmonary; Infusions, Intravenous; Male; Phenylpropionates; Phosphodiesterase 5 Inhibitors; Piperazines; Pulmonary Artery; Purines; Pyridazines; Pyrimidines; Randomized Controlled Trials as Topic; Sildenafil Citrate; Sulfonamides; Sulfones; Tadalafil; Vascular Resistance; Vasodilator Agents | 2014 |
Opportunities and challenges of pharmacotherapy for pulmonary arterial hypertension in children.
Topics: Adolescent; Adult; Bosentan; Calcium Channel Blockers; Child; Child, Preschool; Epoprostenol; Familial Primary Pulmonary Hypertension; Humans; Hypertension, Pulmonary; Iloprost; Infant; Infant, Newborn; Phenotype; Phenylpropionates; Phosphodiesterase 5 Inhibitors; Prognosis; Pulmonary Arterial Hypertension; Pyridazines; Pyrimidines; Receptors, Endothelin; Sildenafil Citrate; Sulfonamides; Tadalafil; Young Adult | 2021 |
3 trial(s) available for tadalafil and macitentan
| Article | Year |
|---|---|
Pharmacotherapy for pulmonary arterial hypertension.
Topics: Acetamides; Adult; Aged; Antihypertensive Agents; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Male; Middle Aged; Pulmonary Arterial Hypertension; Pyrazines; Pyrimidines; Severity of Illness Index; Sulfonamides; Tadalafil; Treatment Outcome; Vascular Resistance | 2020 |
Three- Versus Two-Drug Therapy for Patients With Newly Diagnosed Pulmonary Arterial Hypertension.
Topics: Acetamides; Adult; Aged; Antihypertensive Agents; Double-Blind Method; Drug Therapy, Combination; Endothelin Receptor Antagonists; Female; Humans; Male; Middle Aged; Phosphodiesterase 5 Inhibitors; Pulmonary Arterial Hypertension; Pyrazines; Pyrimidines; Sulfonamides; Tadalafil | 2021 |
Bioequivalence and food effect of a fixed-dose combination of macitentan and tadalafil: Adaptive design in the COVID-19 pandemic.
Topics: Adult; COVID-19; Cross-Over Studies; Drug Therapy, Combination; Fasting; Female; Food-Drug Interactions; Humans; Male; Middle Aged; Pyrimidines; Research Design; Sulfonamides; Tadalafil; Therapeutic Equivalency; Young Adult | 2021 |
8 other study(ies) available for tadalafil and macitentan
| Article | Year |
|---|---|
The Effect of Sorafenib, Tadalafil and Macitentan Treatments on Thyroxin-Induced Hemodynamic Changes and Cardiac Abnormalities.
Topics: Animals; Blood Pressure; Cardiomyopathies; Disease Models, Animal; Echocardiography; Electrocardiography; Heart Defects, Congenital; Heart Rate; Hemodynamics; Male; Mice; Myocardial Contraction; Niacinamide; Organ Size; Phenylurea Compounds; Pyrimidines; Sorafenib; Sulfonamides; Tadalafil; Thyroxine | 2016 |
Plasma Drug Concentrations in Patients with Pulmonary Arterial Hypertension on Combination Treatment.
Topics: Adult; Aged; Bosentan; Case-Control Studies; Drug Interactions; Drug Therapy, Combination; Endothelin Receptor Antagonists; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Phenylpropionates; Phosphodiesterase 5 Inhibitors; Pyridazines; Pyrimidines; Sildenafil Citrate; Sulfonamides; Tadalafil | 2017 |
Choice of Initial Oral Therapy for Pulmonary Arterial Hypertension: Age and Long-Term Survival.
Topics: Administration, Oral; Age Factors; Bosentan; Drug Therapy, Combination; Endothelin Receptor Antagonists; Female; Humans; Hypertension, Pulmonary; Male; Middle Aged; Phenylpropionates; Phosphodiesterase 5 Inhibitors; Pyridazines; Pyrimidines; Retrospective Studies; Sildenafil Citrate; Sulfonamides; Tadalafil | 2018 |
A case of suspected portal-pulmonary hypertension due to hepatitis C virus infection.
Topics: Adult; Antiviral Agents; Cardiac Catheterization; Echocardiography; Echocardiography, Doppler; Endothelin Receptor Antagonists; Female; Hepatitis C, Chronic; Humans; Hypertension, Portal; Liver Cirrhosis; Phosphodiesterase 5 Inhibitors; Pulmonary Arterial Hypertension; Pyrimidines; Sulfonamides; Sustained Virologic Response; Tadalafil; Treatment Outcome; Tricuspid Valve Insufficiency; Ventricular Dysfunction, Right | 2020 |
Characteristics of Pulmonary Arterial Hypertension in Patients with Systemic Sclerosis and Anticentriole Autoantibodies.
Topics: Aged; Aged, 80 and over; Antibodies, Antinuclear; Autoantibodies; Bosentan; Cardiac Catheterization; Centrioles; Drug Therapy, Combination; Endothelin Receptor Antagonists; Epoprostenol; Female; Forced Expiratory Volume; Humans; Imatinib Mesylate; Protein Kinase Inhibitors; Pulmonary Arterial Hypertension; Pulmonary Diffusing Capacity; Pyrimidines; Scleroderma, Systemic; Sildenafil Citrate; Sulfonamides; Tadalafil; Tomography, X-Ray Computed; Vasodilator Agents | 2020 |
Initial combination therapy of macitentan and tadalafil in pulmonary arterial hypertension.
Topics: Drug Therapy, Combination; Endothelin Receptor Antagonists; Humans; Pulmonary Arterial Hypertension; Pyrimidines; Sulfonamides; Tadalafil | 2020 |
Bioequivalence of macitentan and tadalafil given as fixed-dose combination or single-component tablets in healthy subjects.
Topics: Adolescent; Adult; Area Under Curve; Cross-Over Studies; Delayed-Action Preparations; Drug Combinations; Female; Healthy Volunteers; Humans; Hypoglycemic Agents; Male; Metformin; Middle Aged; Pyrimidines; Sulfonamides; Tablets; Tadalafil; Therapeutic Equivalency; Young Adult | 2020 |
Modification Tadalafil and Macitentan tablets to aerosol.
Topics: Aerosols; Humans; Hypertension, Pulmonary; Particle Size; Pyrimidines; Sulfonamides; Tablets; Tadalafil | 2022 |